Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis
Status:
Completed
Trial end date:
2019-12-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of tobramycin inhalation solution (TIS)
once daily compared tot placebo in patients with non-CF bronchiectasis. The primary endpoint
is a reduction of exacerbations of the disease during the treatment period. Next to this
parameter the investigators expect to show a significant beneficial effect on lung function
parameters, QoL, bacterial load of pathogens in sputum and tobramycin resistance.